The LCP nanoparticles could co-deliver the chemotherapeutic drug gemcitabine monophosphate (GMP) and siRNA specific to the undruggable cMyc oncogene (cMyc siRNA) into the cytoplasm and effectively induce the apoptosis of tumor cells and the anti-tumor activity in both subcutaneous and orthotopic models of aggressive non-small-cell lung cancer over either cMyc siRNA or GMP therapy alone. The gene discussed is MYC; the disease is non-small cell lung carcinoma.